Introduction: A clinical diagnosis of I-cell disease was established in an infant with coarse face, hyperplastic gums, severe growth deficiency, skeletal deformities and retarded psychomotor development.
Patient/method: Albeit, enzyme measurements in our patient leukocytes and serum including arylsulfatase, hexosaminidase, alpha-fucosidase, iduronate-sulphatase and beta-galactosidase showed no significant alteration, in serum an increased activity of beta-glucuronidase was detected. Enzyme studies in fibroblasts showed an abnormal intracellular/extracellular distribution of enzyme activities, and significantly decreased activity of UDP-N-acetylglucosamine-1-phosphotransferase confirming the diagnosis of I-cell disease.
Results/discussion: In the mother's next pregnancy at 15th week of gestation lysosomal enzyme activities were determined in amniotic fluid and cultured amniotic cells, and the diagnosis of an unaffected fetus was established. Based on our experience we suggest the use of cell cultures for the diagnostics of this rare disease.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Efficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
Lancet
January 2025
Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address:
Background: Dermatomyositis is a chronic autoimmune disease with distinctive cutaneous eruptions and muscle weakness, and the pathophysiology is characterised by type I interferon (IFN) dysregulation. This study aims to assess the efficacy, safety, and target engagement of dazukibart, a potent, selective, humanised IgG1 neutralising monoclonal antibody directed against IFNβ, in adults with moderate-to-severe dermatomyositis.
Methods: This multicentre, double-blind, randomised, placebo-controlled, phase 2 trial was conducted at 25 university-based hospitals and outpatient sites in Germany, Hungary, Poland, Spain, and the USA.
Relationship between high-resolution computed tomography quantitative imaging analysis and physiological and clinical features in antisynthetase syndrome-related interstitial lung disease.
RMD Open
November 2024
Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
Objectives: To explore the association between the extent of CT abnormalities by quantitative imaging analysis (QIA) and clinical/physiological disease parameters in patients with antisynthetase syndrome associated interstitial lung disease (ARS-ILD).
Methods: We analysed 20 patients with antisynthetase antibodies and active ILD enrolled in the Abatacept in Myositis-Associated Interstitial Lung Disease study. High-resolution chest CT was obtained at weeks 0, 24 and 48 and QIA scored the extent of ground glass (quantitative score for ground glass), fibrosis (quantitative score for lung fibrosis, QLF) and total ILD (quantitative ILD, QILD).
Design of a randomised controlled hybrid trial of nintedanib in patients with progressive myositis-associated interstitial lung disease.
BMC Pulm Med
October 2024
Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA.
Background: The Myositis Interstitial Lung Disease Nintedanib Trial (MINT) is a hybrid trial, which is enrolling patients both at local sites and remotely via a decentralised site. The trial will investigate the efficacy and safety of nintedanib in patients with progressive myositis-associated interstitial lung disease (MA-ILD).
Methods/design: MINT is an exploratory, prospective randomised placebo-controlled trial.
Advances in small-molecule fluorescent probes for the study of apoptosis.
Chem Soc Rev
September 2024
Institute of Pharmaceutical Biotechnology, School of Biology and Food Engineering, Suzhou University, Suzhou 234000, P. R. China.
Article Synopsis
- Apoptosis is a controlled process of cell death linked to many diseases like cancer and neurodegenerative disorders, but its mechanisms are still not fully understood due to challenges in observing it in living systems.* -
- Recent advancements in small-molecule fluorescent probes (SMFPs) have gained attention for their ability to visualize and study apoptosis in real-time, aiding in diagnostics and therapies.* -
- This review outlines the design mechanisms of SMFPs, addresses their current limitations, and discusses future prospects for their use in understanding apoptosis and related diseases.*
Silver ciprofloxacin (CIPAG): a multitargeted metallodrug in the development of breast cancer therapy.
J Biol Inorg Chem
March 2024
Department of Chemistry, University of Ioannina, 45110, Ioannina, Greece.
The anti-proliferative activity of the known metalloantibiotic {[Ag(CIPH)]NO∙0.75MeOH∙1.2HO} (CIPAG) (CIPH = ciprofloxacin) against the human breast adenocarcinoma cancer cells MCF-7 (hormone dependent (HD)) and MDA-MB-231 (hormone independent (HI)) is evaluated.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!